Back
27 March 2025
The ITA, on behalf of United World Wrestling (UWW), confirms that the athlete Dmitriy Baboryko has agreed¹ to the consequences imposed for his anti-doping rule violation (“ADRV”).
The athlete tested positive for the prohibited substance Tamoxifen following an in-compteition doping control performed by the ITA on 23 October 2024 during the U23 UWW World Championship held in Tirana, Albania.
Tamoxifen is prohibited under the WADA Prohibited List in the category of S4. Hormone and Metabolic Modulators. It is prohibited at all times (in- and out-of-competition) and is classified as a specified substance.
The athlete did not challenge the ADRV and agreed with the consequences that apply, namely a period of ineligibility of two years from 20 December 2024 until 19 December 2026 and disqualification of competitive results from 23 October 2024 onwards.
The relevant stakeholders, namely the World Anti-Doping Agency and the Russian National Anti-Doping Organization, have a right to appeal the consequences imposed before the appeals division of the Court of Arbitration for Sport.
The ITA will not comment further on this case.
¹ Athletes have the right to choose not to have their case referred to a hearing panel. In these instances, the anti-doping organisation will assess the athlete’s case file and establish the applicable consequences pursuant to the anti-doping rules and the athlete will have the right to accept the proposed consequences. If the athlete refuses the proposed consequences, the case is transferred to a hearing panel. This resolution mechanism is provided for in articles 8.3.1 and 8.3.3 of the UWW anti-doping rules and 8.3 of the World Anti-Doping Code and is commonly referred to as an agreement on consequences and is deemed an UWW/ITA decision. The athlete’s National Anti-Doping Organisation and the World Anti-Doping Agency have the right to appeal the agreement on consequences before the competent appeal body.
